(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% $ 12.00
Live Chart Being Loaded With Signals
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally...
Stats | |
---|---|
Tagesvolumen | 1 520.00 |
Durchschnittsvolumen | 1 701.00 |
Marktkapitalisierung | 144.00 |
EPS | $13.29 ( 2023-06-30 ) |
Last Dividend | $0.110 ( 2021-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 80.00 |
ATR14 | $0 (0.00%) |
Taisho Pharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Taisho Pharmaceutical Finanzdaten
Annual | 2023 |
Umsatz: | $301.38B |
Bruttogewinn: | $177.85B (59.01 %) |
EPS: | $231.72 |
FY | 2023 |
Umsatz: | $301.38B |
Bruttogewinn: | $177.85B (59.01 %) |
EPS: | $231.72 |
FY | 2022 |
Umsatz: | $268.20B |
Bruttogewinn: | $163.83B (61.09 %) |
EPS: | $161.12 |
FY | 2021 |
Umsatz: | $282.04B |
Bruttogewinn: | $175.99B (62.40 %) |
EPS: | $41.71 |
Financial Reports:
No articles found.
Taisho Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.113 | 2021-03-29 |
Last Dividend | $0.110 | 2021-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.223 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.67 | -- |
Div. Sustainability Score | 7.14 | |
Div.Growth Potential Score | 3.89 | |
Div. Directional Score | 5.51 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SBGSY | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
FOJCY | Ex Dividend Junior | 2023-09-29 | Annually | 0 | 0.00% | |
AAGIY | Ex Dividend Knight | 2023-09-07 | Annually | 0 | 0.00% | |
WTKWY | Ex Dividend Knight | 2023-08-29 | Annually | 0 | 0.00% | |
MHGU | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
CNLHO | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
SPXCY | Ex Dividend Knight | 2023-05-05 | Quarterly | 0 | 0.00% | |
HGKGY | Ex Dividend Knight | 2023-08-31 | Annually | 0 | 0.00% | |
APNHY | Ex Dividend Junior | 2023-09-21 | Sporadic | 0 | 0.00% | |
NUBC | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0263 | 1.500 | 9.47 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00838 | 1.200 | 9.72 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0104 | 1.500 | -0.996 | -1.494 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.04 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 87.55 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.572 | 1.000 | 3.80 | 3.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0590 | 1.000 | -0.819 | -0.819 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.319 | 0.800 | -1.209 | -0.967 | [0.5 - 2] |
Total Score | 7.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.49 | 1.000 | 8.23 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0104 | 2.50 | -0.640 | -1.494 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00282 | 1.500 | 9.93 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 769.92 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0341 | 1.500 | -3.56 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.197 | 1.000 | 7.58 | 0 | [0.1 - 0.5] |
Total Score | 3.89 |
Taisho Pharmaceutical
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.